Loncastuximab Tesirine in WM

计划入组 21 人 · 首次发布于 2022 年 1 月 13 日

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

计划入组 5 人 · 首次发布于 2022 年 12 月 21 日

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

计划入组 24 人 · 首次发布于 2023 年 8 月 2 日

Loncastuximab tesirine(Zynlonta)

Loncastuximab

Rovalpituzumab tesirine

ADC Therapeutics

Switzerland

ADC Therapeutics' Zynlonta Faces Competition, Poised for Potential Second-Line DLBCL Approval

Loncastuximab Tesirine Shows Promise in Treating HLH Associated with DLBCL

Loncastuximab Tesirine Shows High Efficacy in Treating High-Risk Lymphoma Types